

"Express Mail" mailing label number EL 675 713 911 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on 1/9/01

By: [Signature]
Printed: Nancy Ramos Ted Martinez



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Magna et al.

Title: HUMAN NUCLEOTIDE PYROPHOSPHOHYDROLASE-2

Serial No.: To Be Assigned

Filing Date:

Herewith

Examiner: To Be Assigned

Group Art Unit:

To Be Assigned

Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Applicants respectfully submit under 37 C.F.R. 1.98(3)(d) that copies of the references are not included herein as copies were previously cited by or submitted to the Office in parent application Serial No. 08/996,083, filed December 22, 1997 and in application Serial No. 09/429,516, filed October 28, 1999, from which we are claiming priority under 35 U.S.C. 120.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the

documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Incyte Pharmaceuticals, Inc. Deposit Account No. **09-0108**. **A duplicate copy of this communication is enclosed.**

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: 09 January 2001



Richard C. Ekstrom

Reg. No. 37,027

Direct Dial Telephone: (650) 843-7352

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

U.S. Department of Commerce, Patent and Trademark Office				Atty Docket No.		Serial No.	
				PF-0420-2 DIV		To Be Assigned	
LIST OF REFERENCES CITED BY APPLICANTS				Applicants			
(Use several sheets if necessary)				Magna et al.			
				Filing Date		Group	
				Herewith		To Be Assigned	
U.S. Patent Documents							
*Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate	
Foreign Patent Documents							
						Translation	
	Document	Date	Country	Class	Subclass	Yes	No
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	1	Swan, A. et al., "Submicroscopic crystals in osteoarthritic synovial fluids" <u>Ann.Rheum.Dis.</u> (1994) 53:467-470.					
	2	Lohmander, L.S. et al., "METALLOPROTEINASES, TISSUE INHIBITOR, AND PROTEOGLYCAN FRAGMENTS IN KNEE SYNOVIAL FLUID IN HUMAN OSTEOARTHRITIS" <u>Arthritis Rheum.</u> (1993) 36:181-189.					
	3	Ryan, L.M. et al., "Adenosine Triphosphate Levels in Human Plasma" <u>J.Rheumatol.</u> (1996) 23:214-219.					
	4	Park, W. et al., "Inorganic Pyrophosphate Generation from Adenosine Triphosphate by Cell-Free Human Synovial Fluid" <u>J.Rheumatol.</u> (1996) 23:665-671.					
	5	Derfus, B.A. et al., "ARTICULAR CARTILAGE VESICLES GENERATE CALCIUM PYROPHOSPHATE DIHYDRATE-LIKE CRYSTALS IN VITRO" <u>Arthritis Rheum.</u> (1992) 35:231-240.					
	6	Cardenal, A. et al., "IDENTIFICATION OF A NUCLEOTIDE PYROPHOSPHOHYDROLASE FROM ARTICULAR TISSUES IN HUMAN SERUM" <u>Arthritis Rheum.</u> (1996) 39:252-256.					
	7	Cardenal, A. et al., "SPECIFICITY OF A PORCINE 127-KD NUCLEOTIDE PYROPHOSPHOHYDROLASE FOR ARTICULAR TISSUES" <u>Arthritis Rheum.</u> (1996) 39:245-251.					
	8	Masuda, I. et al., "A unique ectonucleotide pyrophosphohydrolase associated with porcine chondrocyte-derived vesicles" <u>J.Clin.Invest.</u> (1995) 95:699-704 (abstract attached)					
	9	Masuda, I. et al., "Molecular cloning and expression of a porcine chondrocyte nucleotide pyrophosphohydrolase" <u>Gene</u> (1997) 197:277-287 (abstract attached)					
	10	Lorenzo, P. et al., "Cloning and Deduced Amino Acid Sequence of a Novel Cartilage Protein (CILP) Identifies a Proform Including a Nucleotide Pyrophosphohydrolase", <u>J. Biol. Chem.</u> 273: 23469-23475 (1998)					
Examiner			Date Considered				
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.</p>							

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.